Cargando…

Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort

INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has led to worldwide vaccination development efforts. In December 2020 the Pfizer BNT162b2 vaccine was approved in the United States. This study describes the first BNT162b2 vaccine dose effect on a large cohort. METHODS: This retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shachor-Meyouhas, Yael, Hussein, Khetam, Szwarcwort-Cohen, Moran, Weissman, Avi, Mekel, Michal, Dabaja-Younis, Halima, Hyams, Gila, Horowitz, Netanel A., Kaplan, Marielle, Halberthal, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537975/ https://www.ncbi.nlm.nih.gov/pubmed/34702617 http://dx.doi.org/10.1016/j.vaccine.2021.10.016

Ejemplares similares

COVID-19: Healthcare Workers May Be at Greater Risk Outside Their Work Environment—A Retrospective Observational Study
por: Hussein, Khetam, et al.
Publicado: (2022)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
por: Hussein, Khetam, et al.
Publicado: (2022)

Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2023)

Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2022)

Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
por: Braun, Eyal, et al.
Publicado: (2022)

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
por: Goshen-Lago, Tal, et al.
Publicado: (2021)

SARS-CoV-2 and seasonal influenza: similarities and disparities
por: Dabaja-Younis, Halima, et al.
Publicado: (2022)

Q Fever Osteoarticular Infection in Children
por: Dabaja-Younis, Halima, et al.
Publicado: (2020)

2462. The impact of the COVID-19 pandemic on hospital-acquired infections and multidrug-resistant organisms, and comparison with seasonal influenza
por: Dabaja-Younis, Halima, et al.
Publicado: (2023)

1559O Efficacy and toxicity of BNT162b2 vaccine in cancer patients
por: Ben-Aharon, I., et al.
Publicado: (2021)

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

TO VACCINATE OR NOT TO VACCINATE – BNT162b2 SEROCONVERSION RATE AND SIDE EFFECTS AMONG POLISH HEALTHCARE WORKERS
por: Siewert, Bartosz, et al.
Publicado: (2022)

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
por: Gurion, Ronit, et al.
Publicado: (2021)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
por: Gurion, R., et al.
Publicado: (2022)

‘Becoming a Physician’–medical students get acquainted with disadvantaged populations, and practise sensitive and effective communication
por: Riskin, Arieh, et al.
Publicado: (2015)

The Impact of Respiratory Symptoms on the Risk of Serious Bacterial Infection in Febrile Infants < 60 Days Old
por: Masarweh, Kamal, et al.
Publicado: (2023)

460 Bacteremic vs Non-bacteremic Febrile Episodes in Children with Cancer: Prospective Multicenter Study in 5 Centers in Israel
por: Averbuch, Diana, et al.
Publicado: (2014)

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment
por: Buttiron Webber, Tania, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
por: Palich, R., et al.
Publicado: (2021)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
por: Brosh-Nissimov, Tal, et al.
Publicado: (2021)

BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals
por: Mor, Orna, et al.
Publicado: (2022)

P050: Containment of methicillin resistant staphylococcus aureus (MRSA) outbreak in a neonatal intensive care unit (NICU)
por: Eluk, O, et al.
Publicado: (2013)

Delayed discharges from a tertiary teaching hospital in Israel- incidence, implications, and solutions
por: Berger, Gidon, et al.
Publicado: (2020)

BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women
por: Rosenberg-Friedman, Michal, et al.
Publicado: (2021)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
por: Bader, Guy, et al.
Publicado: (2023)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Transplacental transfer of SARS-CoV-2 antibodies in recovered and BNT162b2-vaccinated patients
por: Treger, Sharon, et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ijb44a53r4jfihf6ic30cr8ed9